SOUTH EASTON, Massachusetts, June 4, 2020/ PRNewswire/– Pressure BioSciences, Inc. (OTCQB: PBIO) (” PBI” or the “Company”), a leader in the advancement and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage markets, today announced the invoice of an order for the 12 th and final system arranged to be integrated in the Company’s preliminary production run of its innovative BaroShear ™ K45 processing system. Based upon the Business’s exclusive Ultra Shear Technology ™ (UST ™) platform, the BaroShear K45 is a special and powerful nanoemulsification system developed to resolve one of the most vital problems facing the international hemp-derived cannabinoid industry today: how to make hemp-derived cannabinoid oil effectively soluble in water, to optimize absorption and bioavailability when consumed or applied. The cannabidiol market is forecasted to surpass $20 B by 2024 ( Forbes, May 2019).
Low or commonly varying levels of hemp-derived cannabinoid absorption and biological accessibility is an important concern that may considerably impact the bioavailability and effectiveness of the possible advantages of hemp-derived cannabinoid items on the market today.
The Business previously revealed plans for its very first manufacturing run of twelve (12) BaroShear K45 processing systems with estimated completion times during the fourth quarter of2020 Due to inadequacies caused by the COVID-19 pandemic, the Company now thinks that all 12 systems will be finished in time for shipment and installation to take place throughout the first quarter of2021
Mr. Kenneth F. Micciche, Director of PBI’s UST Program, said: “The order for the last readily available BaroShear K45 system from our preliminary production run was received from an interesting young company out of Massachusetts called Canopy CBD Farms, LLC. They use only the highest quality hemp biomass readily available and the most current processing innovations to meet or surpass market standards.
Mr. John Westlake, Creator and President of Canopy CBD Farms, LLC., commented: “Scientific information highly supports the vital understanding that hemp-derived cannabinoid oil needs to be processed into an efficiently water-soluble, long-term steady nanoemulsion to accomplish the greatest quality hemp-derived cannabinoid items possible. After an exhaustive review of readily available technologies, a thorough assessment of UST-processed hemp-derived cannabinoid materials, and a comprehensive and including site visit, we concluded the BaroShear K45 was unrivaled in deep space of nanoemulsion processing platforms. As we are committed to using just the very best equipment in our own production, and convinced that the BaroShear K45 will provide us many competitive advantages in the marketplace, it was an easy decision for us to put this order for the 12 th and last BaroShear K45 system in PBI’s initial production run.”
Mr. Richard T. Schumacher, President and CEO of PBI, commented: “We are very gratified and excited that the initial production run of our BaroShear K45 processing systems has actually offered out. We are likewise pleased that an outstanding, up-and-coming company like Canopy CBD Farms was able to take part in and place an order for the final readily available system in our first manufacturing run. We are positive that the BaroShear K45 will differentiate them in the market with a considerable benefit over their competition.”
Mr. Schumacher continued: “Much development has actually been made in the advancement of this extremely unique and ingenious nanoemulsification processing system. Upon their approval, we expect to ship and install all 12 BaroShear K45 systems during Q1 2021, at which point we will acknowledge approximately $ 2.4 million in profits.
About Canopy CBD Farms, LLC.
Canopy CBD Farms is a state certified Massachusetts hemp processor and manufacturing company.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly allowing, pressure-based solutions for the worldwide life sciences and other markets. Additionally, major new market chances have emerged in the usage of our pressure-based innovations in the following locations: (1) the use of our just recently obtained, patented technology from BaroFold, Inc. (the “BaroFold” innovation) to permit entry into the bio-pharma agreement services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Innovation (” UST”) platform to (i) produce steady nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare greater quality, homogenized, extended shelf-life or space temperature steady low-acid liquid foods that can not be successfully preserved using existing non-thermal technologies.
Forward Looking Declarations
This news release includes forward-looking declarations. These statements connect to future events or our future financial efficiency and involve recognized and unknown dangers, uncertainties and other elements that may trigger our or our market’s real outcomes, levels of activity, efficiency or accomplishments to be materially different from any future results, levels of activity, efficiency or accomplishments expressed, implied or presumed by these positive declarations. In some cases, you can recognize positive statements by terminology such as “may,” “will,” “should,” “could,” “would,” “anticipates,” “plans,” “plans,” “anticipates,” “thinks,” approximates,” “forecasts,” “jobs,” “potential” or “continue” or the unfavorable of such terms and other equivalent terminology. These declarations are just forecasts based upon our present expectations and forecasts about future events. You must not put excessive dependence on these statements. In examining these declarations, you ought to particularly think about different factors. Actual occasions or outcomes might vary materially. These and other aspects may cause our real results to vary materially from any forward-looking declaration. These risks, unpredictabilities, and other aspects consist of, however are not limited to, the dangers and uncertainties gone over under the heading “Threat Aspects” in the Business’s Yearly Report on Type 10- K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Business undertakes no commitment to update any of the details included in this release, other than as otherwise needed by law. Due to rounding, numbers provided throughout this and other files may not add up specifically to the overalls provided and portions may not specifically reflect the outright figures.
For additional information about PBI and this press release, please click on the following website link:
Please visit us on Facebook, LinkedIn, and Twitter.
Richard T. Schumacher, President and CEO
Kenneth F. Micciche, Director– UST Program
SOURCE Pressure BioSciences, Inc.